Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Genevector Initiates Clinical Study for JWK001 in Neovascular Age-Related Macular Degeneration

Fineline Cube Jun 14, 2023

Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first...

Company Drug

Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study

Fineline Cube Jun 14, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...

Company Drug

Croma-Pharma Initiates Phase III Clinical Trial in China for Hyaluronic Acid Dermal Filler

Fineline Cube Jun 13, 2023

Austria-based Croma-Pharma has revealed that the first patient is set to be enrolled in a...

Company Deals R&D

Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research

Fineline Cube Jun 13, 2023

Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement...

Company Deals

Apeloa Pharmaceutical Partners with Zelgen Biopharmaceuticals for CDMO Programs

Fineline Cube Jun 13, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Drug

Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira

Fineline Cube Jun 13, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...

Company Drug

Bio-Thera Solutions’ BAT6026 Receives NMPA Approval for Atopic Dermatitis Clinical Trials

Fineline Cube Jun 13, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced receiving approval from China’s National Medical Products...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Gets EU Approval for Global Phase III Study

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving the green light from EU...

Company Drug

CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study

Fineline Cube Jun 13, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Deals

VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities

Fineline Cube Jun 13, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a...

Company Drug

China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures

Fineline Cube Jun 13, 2023

China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...

Company Drug

Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China

Fineline Cube Jun 13, 2023

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...

Company Drug

Abbisko Therapeutics Initiates Phase II Study for Pimicotinib in Chronic Graft-Versus-Host Disease

Fineline Cube Jun 12, 2023

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing...

Policy / Regulatory

NHSA Launches 2023 NRDL Update Process with New Work Plan and Public Feedback Period

Fineline Cube Jun 12, 2023

The National Healthcare Security Administration (NHSA) has commenced the process for the annual update of...

Company Drug

Genor Biopharma’s Geptanolimab NDA for PTCL Rejected by China’s NMPA

Fineline Cube Jun 12, 2023

China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the National Medical Products Administration...

Company Drug

CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment

Fineline Cube Jun 12, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...

Company Drug

Salubris Pharmaceuticals’ Enarodustat Gains NMPA Approval for Renal Anemia Treatment

Fineline Cube Jun 12, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving market approval from the...

Company Deals

Baheal Pharmaceutical Partners with RabPharma for Commercialization of RAB001 in China

Fineline Cube Jun 12, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...

Policy / Regulatory

CDE Releases 71st Batch of Generic Reference Preparations with Updates and New Injecables

Fineline Cube Jun 12, 2023

The Center for Drug Evaluation (CDE) has released the 71st batch of chemical generic reference...

Posts pagination

1 … 511 512 513 … 662

Recent updates

  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
  • Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength
  • Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Company

Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth

Company

Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.